Pay in 4 interest-free payments of $6.73 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
J Neuropathol Exp Neurol 57 (4), 338342
In small proof-of-concept phase 2 randomized controlled trials (RCTs) in patients with biopsy-confirmed MASH, liraglutide at 1.8 mg/day for 48 weeks (201), semaglutide at 0.4 mg/day for 72 weeks (202), and tirzepatide at 15 mg/week for 52 weeks (203) have been reported to achieve placebo-corrected percentages of participants meeting the criteria for resolution of MASH without worsening fibrosis by 30% (P = 0.019), 42% (P 10%) may lead to diabetes remission (237)
Association of GLP-1 Receptor Agonists With Gastrointestinal Adverse Events . JAMA , 2023
Freeland KR, Wolever TM
Ann Am Thorac Soc 21: 362-363, 2024
US$ 20.35
US$ 20.27
US$ 23.12
US$ 26.39
